Search results for "Neoplastic Syndromes"

showing 9 items of 9 documents

The embryo-placental CD15-positive "vasculogenic zones" as a source of propranolol-sensitive pediatric vascular tumors.

2015

Abstract Objective Propranolol-induced involution is a unique biological feature of some pediatric vascular tumors, for instance infantile hemangioma (IH), cerebral cavernoma or chorioangioma. Currently, the cellular origin of these distinct tumors is unclear. In this study, we tested the hypothesis that propranolol-responsive vascular tumors are derived from common vessel-forming CD15 + progenitor cells which occur in early gestation. The aim of this study was to identify the tumor-relevant CD15 + progenitors at the early stages of embryo-placental development. Materials and methods Human embryo-placental units of 4–8 weeks gestation and pediatric vascular tumors were tested for expression…

0301 basic medicineCD31Pathologymedicine.medical_specialtyPlacentaCD34Lewis X AntigenCD15BiologyHemangioma03 medical and health sciences0302 clinical medicineNeoplastic Syndromes HereditaryPregnancyPlacentamedicineHumansCell LineageHemangioma CapillaryAge of OnsetStem Cell NicheChildNeural tubeInfant NewbornObstetrics and GynecologyPlacentationEndothelial Cellsmedicine.diseaseEmbryo MammalianPropranololPlacentationPregnancy Trimester First030104 developmental biologymedicine.anatomical_structureReproductive MedicineDrug Resistance Neoplasm030220 oncology & carcinogenesisNeoplasms Vascular TissueNeoplastic Stem CellsFemaleHemangiomaImmunostainingDevelopmental BiologyPlacenta
researchProduct

Novel mutations of the MET proto-oncogene in papillary renal carcinomas.

1999

Hereditary papillary renal carcinoma (HPRC) is characterized by multiple, bilateral papillary renal carcinomas. Previously, we demonstrated missense mutations in the tyrosine kinase domain of the MET proto-oncogene in HPRC and a subset of sporadic papillary renal carcinomas. In this study, we screened a large panel of sporadic papillary renal carcinomas and various solid tumors for mutations in the MET proto-oncogene. Summarizing these and previous results, mutations of the MET proto-oncogene were detected in 17/129 sporadic papillary renal carcinomas but not in other solid tumors. We detected five novel missense mutations; three of five mutations were located in the ATP-binding region of t…

AdenomaModels MolecularCancer ResearchProtein ConformationDNA Mutational AnalysisMolecular Sequence DataHereditary Papillary Renal Cell CarcinomaBiologymedicine.disease_causeTransfectionProto-Oncogene MasReceptor tyrosine kinaseMiceAdenosine TriphosphateNeoplastic Syndromes HereditaryProto-OncogenesGeneticsCarcinomamedicineMissense mutationAnimalsHumansPoint MutationAmino Acid SequencePhosphorylationCodonMolecular BiologyKidneyMutationBinding SitesSequence Homology Amino AcidPoint mutation3T3 CellsDNA NeoplasmProto-Oncogene Proteins c-metmedicine.diseaseCarcinoma PapillaryKidney NeoplasmsNeoplasm Proteinsmedicine.anatomical_structureCell Transformation NeoplasticCancer researchbiology.proteinMutagenesis Site-DirectedTyrosine kinaseProtein Processing Post-TranslationalSequence AlignmentOncogene
researchProduct

Prophylactic Thyroidectomy in 75 Children and Adolescents with Hereditary Medullary Thyroid Carcinoma: German and Austrian Experience

1998

When mutations of the RETproto-oncogene were found in 1993 to account for hereditary medullary thyroid carcinoma (MTC), surgeons obtained the opportunity to operate on patients prophylactically (i. e., at a clinically asymptomatic stage). Whether this approach is justified, and, if so, when and to which extent surgery should be performed remained to be clarified. A questionnaire was sent to all surgical departments in Germany and Austria. All of the patients who fulfilled the following criteria were enrolled: (1) preoperatively proved RET mutation; (2) age/= 20 years, (3) clinically asymptomatic thyroid C cell disease; and (4) TNM classification pT0-1/pNX/pN0-1/M0. Seventy-five patients wer…

AdultCalcitoninMalemedicine.medical_specialtyAdolescentmedicine.medical_treatmentAsymptomaticThyroid carcinomaNeoplastic Syndromes HereditaryGermanymedicineCarcinomaHumansChildLymph nodebusiness.industryThyroidThyroidectomymedicine.diseaseSurgerymedicine.anatomical_structureHypoparathyroidismCalcitoninAustriaCarcinoma MedullaryChild PreschoolThyroidectomyFemaleSurgerymedicine.symptombusinessWorld Journal of Surgery
researchProduct

Cylindromatosis (Cyld) gene mutation in T cells promotes the development of an IL-9-dependent allergic phenotype in experimental asthma

2016

Cylindromatosis (CYLD) is a ubiquitously expressed deubiquitinating enzyme which removes activating ubiquitin residues from important signaling molecules of the NF-κB pathway. In CYLDex7/8 transgenic mice, a naturally occurring short isoform (sCYLD) is overexpressed in the absence of full length CYLD, leading to excessive NF-κB activity. Herein, we investigated the impact of the CYLDex7/8 mutation selectively in T cells on the development of experimental allergic airway disease induced by sensitization and challenge with ovalbumin. Compared with their wildtype littermates, mice bearing the T cell-specific mutation (CD4+CYLDex7/8) display stronger eosinophilia and mucus production in the lun…

CD4-Positive T-Lymphocytes0301 basic medicineSkin Neoplasmsmedicine.medical_treatmentT cellImmunologyGene mutationImmunoglobulin Emedicine.disease_causeTh9 cellsDeubiquitinating enzymeMice03 medical and health sciencesNeoplastic Syndromes HereditaryHypersensitivitymedicineAnimalsHumansSensitizationMice KnockoutMutationbiologyTumor Suppressor ProteinsInterleukin-9Cylindromatosis (turban tumor syndrome) geneIL-9AsthmaDeubiquitinating Enzyme CYLDEosinophilsMice Inbred C57BLMucusOvalbumin030104 developmental biologymedicine.anatomical_structureCytokineModels AnimalMutationImmunologybiology.proteinCellular Immunology
researchProduct

Painful papule on the right arm of a woman.

2018

Leiomyosarcomamedicine.medical_specialtySkin Neoplasmsbusiness.industryPapuleDermatologyMiddle AgedDermatologyNeoplastic Syndromes HereditaryLeiomyomatosisUterine NeoplasmsmedicineArmHumansFemalemedicine.symptombusinessClinical and experimental dermatology
researchProduct

Hereditary ovarian cancer.

2008

Apoptosis is a form of cell death that permits the removal of damaged, senescent or unwanted cells in multicellular organisms, without damage to the cellular microenvironment. Defective apoptosis represents a major causative factor in the development and progression of cancer. The majority of chemotherapeutic agents, as well as radiation, utilize the apoptotic pathway to induce cancer cell death. Resistance to standard chemotherapeutic strategies also seems to be due to alterations in the apoptotic pathway of cancer cells. Recent knowledge on apoptosis has provided the basis for novel targeted therapies that exploit apoptosis to treat cancer. These new target include those acting in the ext…

Oncologymedicine.medical_specialtyendocrine system diseasesColorectal cancerMLH1Germline mutationNeoplastic Syndromes HereditaryInternal medicineGenetic predispositionMedicineHumansGenetic Predisposition to DiseaseGenetic testingOvarian Neoplasmsmedicine.diagnostic_testbusiness.industryBRCA mutationHematologymedicine.diseasePrognosisfemale genital diseases and pregnancy complicationsovarian cancerOncologyMSH2FemalebusinessOvarian cancer
researchProduct

Understanding the clinical behavior of relapsed colon cancers with microsatellite instability relative to BRAF mutations

2019

Background Microsatellite instable/deficient mismatch repair (MSI/dMMR) metastatic colorectal cancers have been reported to have a poor prognosis. Frequent co-occurrence of MSI/dMMR and BRAFV600E complicates the association. Patients and methods Patients with resected stage III colon cancer (CC) from seven adjuvant studies with available data for disease recurrence and MMR and BRAFV600E status were analyzed. The primary end point was survival after recurrence (SAR). Associations of markers with SAR were analyzed using Cox proportional hazards models adjusted for age, gender, performance status, T stage, N stage, primary tumor location, grade, KRAS status, and timing of recurrence. Results A…

Proto-Oncogene Proteins B-rafdeficient mismatch repairrecurrenceBrain Neoplasmsbusiness.industryGastrointestinal tumorMicrosatellite instabilityHematologyPrognosismedicine.diseasedigestive system diseasesText miningcolon cancerOncologyNeoplastic Syndromes HereditaryColonic NeoplasmsmedicineCancer researchHumansmicrosatellite instabilityNeoplasm Recurrence LocalColorectal NeoplasmsbusinessAnnals of Oncology
researchProduct

Familial risk-colorectal cancer: ESMO Clinical Practice Guidelines.

2013

J. Balmana1, F. Balaguer2, A. Cervantes3 & D. Arnold4, on behalf of the ESMO Guidelines Working Group* Department of Medical Oncology, Hospital Vall d’Hebron, Vall d’Hebron Institute of Oncology (VHIO), Universitat Autonoma de Barcelona, Barcelona; Department of Gastroenterology, Hospital Clinic, CIBERehd, IDIBAPS, University of Barcelona, Barcelona; Department of Hematology and Medical Oncology, INCLIVA, University of Valencia, Valencia, Spain; Department of Medical Oncology, Tumor Biology Clinic, Albert Ludwigs University, Freiburg, Germany;

Riskmedicine.medical_specialtyColorectal cancerChemopreventionDNA Mismatch RepairDNA GlycosylasesNeoplastic Syndromes Hereditaryhealth services administrationMedicineHumansGenetic Predisposition to DiseaseGenetic TestingMultiple PolypsSigmoidoscopyEarly Detection of CancerAgedTumor biologybusiness.industryBrain NeoplasmsGeneral surgeryHematologyColonoscopyFamilial riskMiddle Agedmedicine.diseaseColorectal Neoplasms Hereditary NonpolyposishumanitiesClinical PracticeEuropeOncologyAdenomatous Polyposis Colipopulation characteristicsFemaleMicrosatellite InstabilitybusinessColorectal NeoplasmsColorectal Surgerygeographic locationsAnnals of oncology : official journal of the European Society for Medical Oncology
researchProduct

Thymoma and paraneoplastic myasthenia gravis

2010

Paraneoplastic autoimmune diseases associate occasionally with small cell lung cancers and gynecologic tumors. However, myasthenia gravis (MG) occurs in at least 30% of all patients with thymomas (usually present at MG diagnosis). These epithelial neoplasms almost always have numerous admixed maturing polyclonal T cells (thymocytes). This thymopoiesis-and export of mature CD4(+)T cells-particularly associates with MG, though there are rare/puzzling exceptions in apparently pure epithelial WHO type A thymomas. Other features potentially leading to inefficient self-tolerance induction include defective epithelial expression of the autoimmune regulator (AIRE) gene and/or of major histocompatib…

ThymomaThymomaT-LymphocytesGenes MHC Class IIImmunologyCellThymus Glandmedicine.disease_causeAutoantigensAutoimmunityhemic and lymphatic diseasesMyasthenia GravisHumansImmunology and AllergyMedicineLymphopoiesisPolyendocrinopathies AutoimmuneAutoantibodiesMHC class IIbiologybusiness.industryLymphopoiesisFOXP3Epithelial Cellsmedicine.diseaseAutoimmune regulatorMyasthenia gravismedicine.anatomical_structureImmunoglobulin GImmunologybiology.proteinbusinessParaneoplastic Syndromes Nervous SystemTranscription FactorsAutoimmunity
researchProduct